Table 2.

Studies demonstrating the efficacy and safety of rimexolone 1 % for postoperative inflammation

Study parameters	Bron et al. [39]	Assil et al. [7]	Kavuncu et al. [40]	Yaylali et al. [41]	Hirneiss et al. [42]
Comparator	Placebo	Placebo	PA	PA	PA and ketorolac
No. of patients	182	197	80	48	45
Treatment duration (weeks)	2	Up to 2	2	2	4
Patients with resolution of ACIa at final visit ( %)	Rimexolone—60 %	Rimexolone—60 %	Not reportedb	Not reportedb	Not reportedb
	Vehicle—28 %	Placebo—32 %
Mean IOP at final visit	No perceptible changes in IOP	Mean decrease in IOP in both treatment groups compared to baseline	Rimexolone—13.0 ± 3.2 mmHg	Rimexolone—11.6 ± 1.4 mmHg	Rimexolone—13.25 mmHg
					PA group—14.60 mmHg
			PA group—11.7 ± 2.9 mmHg	PA group—10.8 ± 1.3 mmHg	Ketorolac group—13.73 mmHg
Clinically significant increases in IOP (≥ 10 mmHg)	Not reported	n = 2 for rimexolone;	Not reported	Not reported	Not reported
		n = 2 for placebo

ACI anterior chamber inflammation, IOP intraocular pressure, PA prednisolone acetate

^aResolution of ACI defined as anterior chamber cell count <5 and flare Grade 0 (none)

^bThe study did not report the percentages of patients with resolution of ACI; instead, mean cell and flare at study visits were reported